TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

Benzinga Logo Benzinga By Business Wire
Securities Fraud Investigation Into Beta Bionics, Inc. (BBNX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

The Law Offices of Frank R. Cruz announced an investigation into Beta Bionics, Inc. for possible federal securities law violations. The investigation was triggered after Beta Bionics reported preliminary Q4 2025 results showing new patient starts growth of 36% year-over-year, down significantly from 68% in the prior quarter. The stock fell 37% ($11.85) to $20.15 per share on January 9, 2026, following the announcement.

Insights
ABBV   positive

Up 30% YTD, record revenue from drugs like SKYRIZI and RINVOQ, raised 2026 outlook, trading at reasonable 19x forward earnings


BBNX   negative

The company faces a securities fraud investigation, reported a significant slowdown in patient growth metrics (36% vs. 68% prior quarter), and experienced a severe 37% stock price decline, resulting in investor losses.